RU2441399C2 - Protein-free infant food - Google Patents

Abstract

FIELD: food industry. ^ SUBSTANCE: this invention covers food for 0-36 month aged infants. A composition comprising free amino acids as a single source of protein, source of fat acids comprising long-chain polyunsaturated fatty acids (LCPUFA), source of carbonhydrates comprising assimilable and non-assimilable carbonhydrates and bifidus bacteria was proposed for treatment of the patients suffering from tormina, astriction, snivel, sniffle, vomit, diarrhea, feces cruentae, mucus in defecation, spots, eczema, gastroesophageal reflux, eosinophilic esophagitis or asthma, allergy for cow milk and/or intolerance to dietary protein, and/or infections. Herewith, non-assimilable carbonhydrates are chosen from milk protein-free source, and bifidus bacteria are dietary protein-free, and the whole composition is essentially intact protein-free. Besides, assimilable carbonhydrate component contains less than 2 mass percent of lactose from overall assimilable carbonhydrates. Fat component includes 0.1-5 mass percent of LCPUFA from overall fat acids content. As an alternative, this composition is applied for stimulation of immune system maturation of the infants suffering from atopic diseases. ^ EFFECT: improvement of infant health without risks of adverse allergic reaction. ^ 25 cl, 2 dwg, 3 tbl, 1 ex

Description

The present invention relates to enhancing the health of infants through the intake of amino acid-based baby food.

Breastfeeding is the preferred method of breastfeeding. However, often after the initial period of breastfeeding of infants, it is stopped, and then the infant's diet contains mainly only milk mixture ("baby food").

However, in a small group of infants, breastfeeding or traditional baby food causes negative reactions, such as pain and allergic reactions. People suffering from allergies may have difficulty digesting or metabolizing certain substances in food, which in turn leads to intestinal allergic reactions or systemic allergic reactions. Allergic reactions are mainly caused by the protein fraction of the food product. To reduce unwanted effects, it is often necessary to significantly change the diet.

For the prevention of an allergic reaction to a protein in the formula of the formula for baby food, hydrolyzed milk protein, amino acids and non-milk proteins, for example soy protein and other nutritional components that do not cause allergic reactions, are used.

Known infant formula formulations comprising amino acids as a nitrogen source, which include Neocate ^™ for use in patients suffering from allergies, gastrointestinal upsets, eczema, malabsorption syndrome or digestive disorders.

In the prior art, a small number of different sources of nutrients are used to prevent allergens from entering the formula of the baby food mixture by adding these ingredients. However, the disadvantage is that infants are deprived of the positive effects of such additional ingredients.

WO 2005/039319 describes the use of synbiotics in an infant formula, including hydrolyzed protein, which reduces the risk of allergies (page 11, lines 35-37).

WO 2006/091103 describes a nutritional composition comprising synbiotics for the treatment and prevention of immunological disorders, including allergies. It is described that the use of a protein hydrolyzate and / or free amino acids reduces the risk of allergies. The aim of the present invention is to improve the formulation of the formula for baby food for this risk group by providing additional nutritional value, without introducing allergens into the composition.

The authors of the present invention understand that if the original composition of the formula for baby food contains various free amino acids without an intact protein, then this is very unpredictable for the development of intestinal flora. Instead of bifidobacteria and lactobacilli, which are the dominant flora of babies who are normally breastfed, many other types of bacteria, including potentially pathogenic bacteria, predominate in the gastrointestinal tract of babies receiving amino acid-based foods.

The development of a healthy intestinal flora is very important for all infants, as infants often already suffer from weakened immunological function, which often leads to colic, constipation, snotty, sniffling, vomiting, diarrhea, bloody stool, mucus in the stool, rash, or eczema.

The authors of the present invention recognize that the development of a healthy flora is very important for infants receiving a diet containing mainly free amino acids as a protein source. Not wanting to be limited by any theory, the authors of the present invention recognize that good flora, that is, rich in bifidobacteria and Lactobacilli, essentially has a beneficial effect on the maturation of the (mucosal) immune system. Good flora prevents the development of allergies or, at least, reduces the severity of allergies in such infants. Therefore, the authors of the present invention recognize the great importance and beneficial effects of the development of flora on these babies.

Despite the limitations in the formulation of the formula for infant formula for infants at risk, the inventors of the present invention have found that selected certain nutritional oligosaccharides, preferably fructans and / or pectin degradation products, can be added to the basic formulation of the mixture to stimulate the development of flora , without the risk of any adverse allergic reactions.

In the basic formulation of the mixture, no products derived from milk are used, as this may lead to the introduction of milk allergens into the product. Therefore, the prebiotic fibers of the present invention are carefully selected from known prebiotic fibers in order to avoid the addition of milk or other intact and potentially allergenic proteins present in the fibers to the non-allergenic composition.

Unexpectedly, the authors of the present invention found that in the universally recognized model for allergies, when combining prebiotic fibers with probiotic bacteria (preferably bifidobacteria), a synergistic effect is manifested in preventing an allergic reaction. This synergistic effect is potentially very beneficial for infants, but may also be for adults.

In the drawings:

Figure 1 - allergic response to various compositions tested in accordance with internationally recognized vaccination in a mouse model.

Figure 2 - synergistic effect of TD1 ( Bifidobacterium breve ) and dietary fiber (OS) in a mouse model of casein allergy.

In a preferred embodiment, the present invention relates to the use of a composition comprising free amino acids as the sole source of protein, a source of fatty acids, including long chain polyunsaturated fatty acids, a source of carbohydrates, including digestible and non-digestible carbohydrates, and milk-free bifidobacteria, to obtain a composition for treatment individuals suffering from:

a. colic, constipation, snotty, wheezing, vomiting, diarrhea, bloody stool, mucus in the stool, rash, eczema, gastroesophageal reflux, eosinophilic esophagitis or asthma;

b. allergies to cow's milk and / or food protein intolerance; and / or

c. infections where non-digestible carbohydrates are selected from a milk protein-free source, and the entire composition is substantially free of intact protein.

As used herein, the term "single protein source" means that the composition of the present invention (preferably) contains at least 99 wt.% Amino acids of the total protein, preferably at least 99.5 more preferably at least 99 , 9 wt.%.

Additionally, the present invention relates to a composition comprising a protein component, a fat component, an digestible carbohydrate component, an unapproachable carbohydrate component and bifidobacteria, where:

a) the protein component contains more than 99 wt.% free amino acids from all proteins and includes at least the following amino acids: alanine, arginine, aspartic acid, cysteine, glycine, histidine, isoleucine, leucine, methionine, proline, serine, threonine, tryptophan, tyrosine, valine and glutamine;

b) the digestible carbohydrate component contains less than 2 wt.% lactose from all digestible carbohydrates;

c) the non-digestible carbohydrate component includes soluble fructan with an average degree of polymerization (DP) of 2 to 200 and soluble galacturonic acid with an average DP of 2 and 200; and

d) the fat component comprises from 0.1 to 5% by weight of LCPUFA (long chain polyunsaturated fatty acids) of the total fatty acid content.

As shown in FIG. 1, the combination of long chain soluble fructans (LFOS) with acid oligosaccharides (AOS), which in this case is pectin hydrolyzate, works as bifidobacteria when tested in a mouse model. However, it is clear that if oligosaccharides are combined with bifidobacteria, the effect is significantly increased.

In a preferred embodiment of the invention, the nutritional composition includes non-digestible fibers and bifidobacteria, since this composition gives the best results in a mouse model of allergy (see Figure 1). Bifidobacteria breve is preferably used.

Indigestible carbohydrates

Fructans are fructose-based neutral oligosaccharides (> 50% of the monose units are fructose), preferably inulin, fructan and / or fructo-oligosaccharides, most preferably a mixture of long-chain fructo-oligosaccharides (lcFOS) with an average DP of 10 to 60 and short-chain fructo-oligosaccharides ) with an average SP of 3 to 10. A preferred embodiment of the invention comprises a mixture of (lcFOS) and (scFOS) in a ratio of 1: 9, since this ratio is closest to the composition of breast milk oligosaccharides and provides an effective c imulyatsiyu growth of bifidobacteria in infants.

The method of the present invention preferably comprises administering a portion comprising from 0.05 to 25 grams of non-digestible saccharides, preferably from 0.1 to 5 grams. Preferably, the method of the present invention comprises from 0.05 to 25 grams (scFOS), preferably from 0.1 to 5 grams (scFOS). Preferably, the method of the present invention comprises administering indigestible saccharides from 0.05 to 25 grams per day, preferably from 0.1 to 5 grams per day.

Pectin degradation products

Pectin is divided into two main categories: high methoxylated pectin, characterized by a degree of methoxylation above 50% and low methoxylated pectin with a degree of methoxylation below 50%. As used herein, the term “degree of methoxylation” (also referred to as SE or “degree of esterification”) refers to the number of free carboxylic acid groups contained in the esterified (eg, methylation) chain of polygalacturonic acid. Preferably, the pectin of the present invention is obtained from highly methoxylated pectin.

Preferably, pectin is characterized by a degree of methoxylation above 20%, preferably above 30%, even more preferably above 50%.

The pectin used in the method of the present invention has an average degree of polymerization (DP) from 2 to 500, preferably from 10 to 250, and most preferably from 20 to 50. When using a mixture of pectins with different degrees of polymerization, the average DP of acidic oligosaccharides of the mixture is preferably from 3 to 1000, more preferably from 3 to 250, even more preferably from 3 to 50. It was found that a lower DP of oligosaccharides improves palatability and decreases the viscosity of the product if acid oligosaccharides are added to idkoy form.

Pectin is preferably added from 0.1 to 100 grams per day, preferably from 0.4 to 50 grams per day, even more preferably from 1 to 20 grams per day.

A preferred embodiment of the invention includes fructans and pectin degradation products in a ratio of 50: 50-95: 5. Preferably, the ratio is 85:15, since neutral oligosaccharides and acid oligosaccharides are present in breast milk in this ratio.

Probiotic bacteria

Probiotic bacteria suitable for use in the present invention at least have a positive effect on the mouse allergy model, as shown in the examples below. Additionally, probiotics essentially should not contain food allergens. To obtain such probiotic bacteria, special procedures or a culture medium without intact protein are required.

Therefore, a preferred embodiment of the invention includes probiotic bacteria substantially free of intact food protein or food allergens, in particular milk protein substantially absent.

In a preferred embodiment, the probiotic bacteria are bifidobacteria. Even more preferably, the probiotic bacteria are Bifidobacterium breve . Bifidobacteria have a very high tolerance, inducing effects on the mouse models used and, therefore, are preferred. In particular, Bifidobacterium breve is very effective.

In another preferred embodiment of the invention, Bifidobacteria are not viable. This is an advantage because it increases the shelf life of food products, and the immunomodulatory activity of bacteria becomes independent of the number of live bifidobacteria. The experiments showed that the immunostimulating effect of non-viable bacteria is similar, and sometimes even better, than the activity of live bifidobacteria.

The composition of the present invention preferably comprises from 10 ² to 10 ¹³ colony forming units (CFU) of bifidobacteria per gram of dry weight of the composition of the present invention, preferably from 10 ² to 10 ¹² CFU, more preferably from 10 ⁵ to 10 ¹⁰ CFU, most preferably from 10 ⁴ to 5 × 10 ⁹ CFU.

Amino acids

Amino acids can be used in a nutritional formula for feeding young children and infants. However, the composition of the amino acids in the nutritional mixture preferably includes all essential amino acids, with the exception of compositions for patients with phenylketonuria (PKU) and for patients with non-PKU congenital malformations of the metabolism, and is preferably optimal for young children or infants. The authors of the present invention have found that the most optimal amino acid composition should be as close as possible to the amino acid composition of the protein fraction of breast milk. The preferred amino acid composition as a result is shown in Table 1 (see below). In a preferred embodiment of the invention, the composition comprises less than 1 wt.% Peptides of the total protein and more than 99 wt.% Of free amino acids of the total protein, includes at least the following amino acids: alanine, arginine, aspartic acid, cysteine, glycine, histidine, isoleucine, leucine, methionine, proline, serine, threonine, tryptophan, tyrosine, valine and glutamine.

Baby formula

The baby formula of the invention comprises free amino acids as a nitrogen source, fat, including a mixture of fats including LCPUFA, and carbohydrates. Vitamins and minerals are added according to regulatory requirements.

Preferably, the composition of the invention is intended for feeding infants and includes a lipid component, a protein component and a carbohydrate component. Preferably, the lipid component provides from 5 to 50% of all calories, preferably the protein component provides from 5 to 50% of all calories, and preferably the carbohydrate component provides from 15 to 90% of all calories. Preferably, the composition of the present invention is used as a formula for feeding infants, where the lipid component provides from 35 to 50% of all calories, the protein component provides from 7.5 to 12.5% of all calories and the carbohydrate component provides from 40 to 55% of all calories . To calculate% of all calories for the protein component, you need to take the total energy provided by amino acids.

Lcpufa

The LCPUFA content of from 20 to 22 carbon atoms in the composition of the present invention preferably does not exceed 15 wt.% Of the total fat, preferably does not exceed 10 wt.%, Even more preferably does not exceed 5 wt.% Of the total fat. Preferably, the composition comprises at least 0.1 wt.%, Preferably at least 0.25 wt.%, More preferably at least 0.5 wt.%, Even more preferably at least 0.75 wt.% LCPUFA with from 20 to 22 carbon atoms of the total fat content. Preferably, the content of docosahexaenoic acid (DHA) does not exceed 5 wt.%, More preferably it does not exceed 1 wt.% And is at least 0.1 wt.% Of the total fat content. Since it was found that arachidonic acid (AA) effectively reduces the permeability of the intestinal impermeable septum, the composition of the present invention includes relatively high amounts, preferably at least 0.1 wt.%, Even more preferably at least 0.25 wt.%, most preferably at least 0.5 wt.% of the total fat content. Preferably, the AA content does not exceed 5 wt.%, More preferably it does not exceed 1 wt.% Of the total fat content. Excess metabolites from AA can cause inflammation. However, the composition of the present invention preferably comprises AA and DHA in an AA / DHA weight ratio of preferably above 0.25, preferably above 0.5, even more preferably above 1. Preferably, the ratio is below 25.

LCPUFAs are preferably non-fish derived from unicellular oils, available for example from Martek.

Preferred features of the compositions of the present invention are shown in Tables 1-3.

Table 1
The amino acid content in the composition of the present invention Amino acid Units AA content as a percentage of the total AA content (g / 100 g) Baby 0-1 year old Young child 1-10 years old Ala g 3.95 4.01 3.12 3.03 Arg g 6.99 7.02 14.24 13.91 Asp g 6.54 6.57 5.73 5.59 Cys g 2.59 2,58 1.85 2.91 Giu acid g 0.00 0.00 0.00 Giy g 6.15 6.12 5.11 5.01 His g 4.02 3.99 3.71 3.61 lso g 6.15 6.12 5.11 5.01 Leu g 10.56 10.51 8.54 8.32 Lys g 7.19 7.19 6.25 6.11 Meth g 1.68 1,69 4.02 3.90 Phe g 7.51 7.47 7.10 6.93 Pro g 4.73 4.72 5.97 5.82 Ser g 4.60 4.61 3.71 3.61 Thr g 5.18 5.17 4.29 4.19 Try g 2.07 2.08 1.72 1,69 tyr g 4.73 4.72 1.44 1.40 Vai g 6.74 6.74 5.42 5.30 Car g 0.06 0.06 0.10 0.12 tau g 0.19 0.20 0.17 0.17 Giu g 8.42 8.43 12.35 13.39 Total g one hundred one hundred 99.97 one hundred

table 2
Nutritional formula for feeding babies with allergies Nutritional profile of infant formula of the present invention (powder) Units Content / 100 g Content / 100 kcal Protein Equivalent g 13 2.9 Energy kcal 455 one hundred Nitrogen g 2.1 Carbohydrates g 49 10.8 Fat (total) g 23 5.1 (MST) % 33 (LCT) % 67

Table 3
The content of long chain polyunsaturated (DSPN) fatty acids in the composition % fatty acids Preferred Limits +/- 25% Arachidonic acid 0.35 0.26 0.44 Docosahexaenoic acid 0.20 0.15 0.25 Total cerebral palsy 0.55 0.41 0.69

Preferred limits of the oligosaccharide composition are 0.4-1.2 g / 100 ml, where 85 wt.% Are (scFOS) and (lcFOS), and 15 wt.% Is pectin hydrolyzate. Preferably, the ratio of (scFOS) to (lcFOS) is from 2 to 20, even more preferably, the ratio is 9.

In one preferred embodiment, the present invention is a milk and allergen-free, full-dose, powdered composition of the present invention, suitable for reconstitution with water, to provide an enteral nutrition, including:

Component Per 100 g of powder Protein Equivalent (g) 13 Total amino acid content (g) 15,5 Total Fat (g) 23 Sunflower oil (g) four Fractionated Coconut Oil (g) 7 Canola Oil (g) four High Olein Sunflower Oil (g) 6.6 ARASCO ^TM Oil (g) 0.21 DHASCO ^TM Oil (g) 0.11 Carbohydrates: Maltodextrin (g) 49 Prebiotic (g) 5.33 (scFOS) (g) 4.1 (lcFOS) (g) 0.43 CBS (g) 0.8 Probiotic: B. Breve (colony forming units; CFU) 1 × 10 ¹⁰ Other vitamins / minerals / trace elements Balance

The above composition provides about 455 kcal of energy per 100 g of powder.

The composition may be diluted with cold boiled water to obtain a recommended concentration of 15% w / v.

Application

Preferably, the composition is used to treat infants (essentially with an atopic condition) suffering from:

a. colic, constipation, snotty, wheezing, vomiting, diarrhea, bloody stool, mucus in the stool, rash, eczema, gastroesophageal reflux, eosinophilic esophagitis or asthma;

b. allergies to cow's milk and / or food protein intolerance; and / or

c. infections.

Also preferably, the composition can be used to improve stool characteristics in infants suffering from the above symptoms. Essentially, the composition is formulated for infants aged 0 to 3 years. With some adaptations for the amino acid profile (see Table 1), the composition is also suitable for children aged 3 to 10 years. Infants with allergies often suffer from diarrhea, but they also have constipation. Preferably, a composition that can be used to prevent and treat these symptoms includes dietary fiber according to the composition of breast milk, where the ratio (scFOS) / (lcFOS) is 9: 1 and pectin hydrolyzate is additionally present.

EXAMPLES

To determine the immunostimulating effect of oligosaccharides and the probiotic Bifidobacterium breve (TD 1), tests are carried out in accordance with internationally recognized vaccination in a mouse model (Figure 1) and an allergic model (Figure 2).

Materials and methods of vaccination on the model

Harlan C57BI / 6JOIaHsd female mice 6-8 weeks old are housed under normal conditions with a 12-hour night / day cycle and unlimited access to food and water. All experiments were approved by an independent animal experimentation committee (DEC Consult, Bilthoven, The Netherlands).

Diet and oligosaccharide preparations

All animals receive partially refined diets based on AIN-93G (Research Diet Services. Wijk bij Duurstede, Netherlands). All additional oligosaccharide products are replaced with the same amount of total carbohydrates in order to keep this parameter the same. In addition, this approach as a result allows you to compare all carbohydrate compositions of different diets with the guarantee that the intestinal flora has minimal differences between the control and the tested diets in terms of parameters such as the passage through the gastrointestinal tract and fluid retention. Oligosaccharides are mixed with AIN-93G and compressed into granules.

Vaccination protocol and RCH response (skin hypersensitivity reaction)

Vaccination experiments were performed using Influvac (Influvac) (Solvay Pharmaceuticals, Weesp, The Netherlands) season 2002/2003. This is a vaccine of an inactivated influenza virus based on the isolated hemagglutinin (HA) antigens and neuraminidase of three strains of myxovirus influenza in a dose equivalent to 30 μg / ml HA per strain (90 [μg / ml HA in total). An oil adjuvant (Stimune, formerly known as Specol; Cedi-diagnostics, Lelystad, Netherlands) is used for all vaccinations. First, mice are vaccinated and then re-vaccinated subcutaneously (s / c) with a mixture of vaccine and adjuvant 1: 1 with a total volume of 100 μl. Re-vaccination is carried out 21 days after the first vaccination. The experiments are completed 10 days after re-vaccination. Blood samples (do retro-orbital puncture) are taken before the first and second vaccinations and at the end of the experiment. All experiments included negative control groups (indicated as a “false group”) receiving injections of a 1: 1 mixture of PBS and an adjuvant with a total volume of 100 μl. False groups are never used for statistical comparison; they serve only to demonstrate the specificity of vaccine-induced responses. RKG reactions were induced 9 days after re-vaccination sc by injection of 25 μl Influvac into the auricles of both ears. The thickness of the ears was measured twice before vaccination and 24 hours after it using a digital micrometer (Mitutoyo Digimatic 293561, Veenendaal, Netherlands). The RCG response is calculated by subtracting the basal thickness of the ear from the indicator 24 hours after vaccination.

Materials and methods used for the model for allergy to cow's milk protein

Chemical reagents

Casein and whey are obtained from DMV international, Veghel, The Netherlands.

Cholera Toxin is available from Quadratech Diagnostics, Epsom, UK. PBS is available from Cambrex Bio Science, Verviers, Belgium. Elisa Surface Sensitization Buffer is available from Sigma, Alphen aan den Rijn, The Netherlands. Biotin labeled with rat anti-mouse IgE is available from BD Biosciences, Alphen aan den Rijn, The Netherlands. All other chemicals are available from Sigma-Aldrich-Chemie, Zwijndrecht, The Netherlands.

Oral sensitization and substance administration mice

Specific pathogen-free female mice aged 3 to 5 weeks C3H / HeOuJ (n = 4-6 per group) are obtained from Charles River Laboratories (Maastricht, the Netherlands) and are fed on milk protein-free mice (Special Diets Services, Witham, Essex, UK) and contain them in the vivarium of the University of Utrecht (Utrecht University). Animals are maintained and used according to the requirements of the Danish Animal Experiment Commission. Mice are sensitized intra-gastrally (i / g) 0.5 ml of homogenized casein (40 mg / ml PBS) with cholera toxin as adjuvant (CT, 20 μl / ml PBS) using a blunt needle. Control mice received only CT or PBS. Mice are re-vaccinated weekly for 6 weeks, one week after the last sensitization, mice are also injected with / g 100 mg casein.

After that, blood samples are collected and centrifuged (15 minutes at 13500 rpm). Serum is stored at -70 ° C. Mice are sacrificed by displacement of the cervical vertebrae one and a half hours after and / g vaccination.

Allergen-specific skin response

Acute allergen-specific skin response is measured after injection of a specific protein into the auricle. Before and / g administration of substances (t = 0), control, casein sensitized mice were given intracutaneous (w / c) injection in the left ear with 20 μl of homogenized casein (0.5 mg / ml in PBS), respectively. In the right ear, 20 μl of PBS is injected as a control. Also, mice treated with CT and PBS were injected with casein in the ear and PBS as a control. Ear thickness was measured twice using a digital micrometer (Mitutoyo, Veenendaal, Netherlands), 0, 1, 4 and 24 hours after administration. Ear edema with an allergen-specific reaction is calculated by subtracting the basal (0 h) and control (right ear) thickness from the measured value at three different time points (1, 4 and 24 h).

Measurement of serum immunoglobulin and protease-1 levels in mouse mast cells

Concentrations of total IgE and levels of casein or specific serum IgE, IgGI and IgG2a are determined in the serum of euthanized mice using an ELISA. Microlon plates (Greiner, Alphen aan den Rijn, Netherlands) were coated with casein in surface sensitization buffer or rat anti-mouse IgE (1 μg / ml) in PBS for 18 hours at 4 ° C. The plates are washed and blocked for 1 hour with 5% BSA. Serum samples are subjected to several dilutions and incubated for 2 hours at room temperature. The plates are washed 5 times and incubated with 1 μg of biotin labeled with rat anti-mouse IgE for half an hour at room temperature. After washing, the strips are incubated with horseradish peroxidase (HRP) for one hour, washed and detected with o-phenylenediamine (OPD). The reaction was stopped with 4M H ₂ SO ₄ and absorbance was measured at 490 nm on a Benchmark microplate reader (Biorad, California, USA). Mast mast cell serum protease-1 concentrations (mMCP-1) were determined as previously described using a commercially available ELISA kit (Moredun Scientific Ltd., Midlothian, UK).

The vaccination results in the mouse model are shown in Figure 1, which clearly shows that the combination of (dietary fiber and) TD 1 (= Bifidobacterium breve ) provides the strongest effect on the RKG response and is significantly better than only TD1 or any other combination tested.

The casein allergy results in the mouse model are shown in FIG. 2 and demonstrate that the combination of dietary fiber and TD 1 synergistically inhibits the “allergic” RCG response to casein.

Claims (25)

1. The use of a composition comprising free amino acids as the sole source of protein, a source of fatty acids, including long chain polyunsaturated fatty acids, a source of carbohydrates, including digestible and non-digestible carbohydrates and bifidobacteria, to obtain a composition for the treatment of individuals suffering from:
a. colic, constipation, snotty, wheezing, vomiting, diarrhea, bloody stool, mucus in the stool, rash, eczema, gastroesophageal reflux, eosinophilic esophagitis or asthma;
b. allergies to cow's milk and / or food protein intolerance;
and / or infections
however, non-digestible carbohydrates are selected from a source free of milk protein, wherein the bifidobacteria are free of milk protein, and the entire composition is substantially free of intact protein. 2. The use according to claim 1, in which the individual is an infant aged from 0 to 36 months. 3. The use according to claim 1 or 2, in which free amino acids of the total protein content include at least the following amino acids: alanine, arginine, aspartic acid, cysteine, glycine, histidine, isoleucine, leucine, methionine, proline, serine, threonine, tryptophan, tyrosine, valine and glutamine. 4. The use of the composition according to claim 3, in which amino acids provide 5-16 en.% Of the whole composition, fats - 30-60 en.%, Of which LCPUFA provides 0.1-5 en.%, And digestible carbohydrates - 25- 75 en.%. 5. The use according to claim 4, in which LCPUFA provide 0.2-1 en.% Of the total composition. 6. The use according to any one of claims 1, 2, 4, 5, wherein the non-digestible carbohydrates include (i) soluble fructan with an average degree of polymerization from 3 to 200 and (ii) soluble galacturonic acid with an average degree of polymerization from 3 to 200. 7. The use of a composition comprising free amino acids as the sole source of protein; a fatty acid source including long chain polyunsaturated fatty acids;
a source of carbohydrates, including digestible and non-digestible carbohydrates and bifidobacteria, to produce a composition for stimulating the maturation of the immune system in infants with atopic conditions;
however, non-digestible carbohydrates are selected from a source free of milk protein, bifidobacteria are free of milk protein, and the entire composition is substantially free of intact protein. 8. The use according to claim 7, in which free amino acids of the total protein content include at least the following amino acids: alanine, arginine, aspartic acid, cysteine, glycine, histidine, isoleucine, leucine, methionine, proline, serine, threonine, tryptophan, tyrosine, valine and glutamine. 9. The use of the composition according to claim 7 or 8, in which amino acids provide 5-16 en.% Of the whole composition, fats - 30-60 en.%, Of which LCPUFA provides 0.1-5 en.%, And digestible carbohydrates - 25-75 en.%. 10. The use according to claim 9, in which LCPUFA provide 0.2-1 en.% Of the total composition. 11. The use according to any one of claims 7, 8, 10, wherein the non-digestible carbohydrates include (i) soluble fructan with an average degree of polymerization from 3 to 200 and (ii) soluble galacturonic acid with an average degree of polymerization from 3 to 200. 12. A composition comprising a protein component, a fat component, an digestible carbohydrate component, an unapproachable carbohydrate component and bifidobacteria, in which:
the protein component includes free amino acids as the sole source of protein and contains at least the following free amino acids: alanine, arginine, aspartic acid, cysteine, glycine, histidine, isoleucine, leucine, methionine, proline, serine, threonine, tryptophan, tyrosine, valine and glutamine;
assimilable carbohydrate component contains less than 2 wt.% lactose from all assimilable carbohydrates;
the fat component comprises from 0.1 to 5 wt.% LCPUFA of the total fatty acid content, characterized in that the bifidobacteria are free from milk protein, the non-digestible carbohydrate component is selected from a milk protein free source, and includes soluble fructan with an average DP of 2 up to 200 and soluble galacturonic acid with an average SP of 2 and 200. 13. The composition according to p. 12, in which:
the fat component comprises from 0.2 to 1 wt.% LCPUFA of the total fatty acid content. 14. The composition according to p. 12, including non-digestible soluble fructan with an average degree of polymerization from 2 to 200 and non-digestible soluble galacturonic acid with an average degree of polymerization from 2 to 200. 15. The composition according to p. 13, including non-digestible soluble fructan with an average degree of polymerization from 2 to 200 and non-digestible soluble galacturonic acid with an average degree of polymerization from 2 to 200. 16. The composition according to any one of paragraphs.12-15, including Bifidobacterium breve. 17. The composition according to any one of paragraphs.12-15, comprising arachidonic acid and / or docosahexaenoic acid. 18. The composition according to clause 16, comprising arachidonic acid and / or docosahexaenoic acid. 19. The composition according to any one of paragraphs.12-15, in which FOS long chain fructooligosaccharides and FOS short chain fructooligosaccharides are used as fructans. 20. The composition according to clause 16, in which the FOC long-chain fructooligosaccharides and the FOC short-chain fructooligosaccharides are used as fructans. 21. The composition according to p. 18, in which the FOS long-chain fructooligosaccharides and the FOS short-chain fructooligosaccharides are used as fructans. 22. The composition according to claim 19, in which long-chain FOS have an average degree of SP from 10 to 60, and short-chain FOS have an average degree of SP from 3 to 10. 23. The composition according to claim 20 or 21, in which the long-chain FOS have an average degree of SP from 10 to 60, and the short-chain FOS have an average degree of SP from 3 to 10. 24. The composition according to any one of paragraphs.12-15, 18, 20-22, in which the product is a powder or liquid. 25. A composition comprising free amino acids as the sole source of protein, a source of fatty acids, including long chain polyunsaturated fatty acids, a source of carbohydrates, including digestible and non-digestible carbohydrates, and bifidobacteria, for use in treating an individual suffering from:
(a) colic, constipation, snotty, wheezing, vomiting, diarrhea, bloody stool, mucus in the stool, rash, eczema, gastroesophageal reflux, eosinophilic esophagitis or asthma;
(b) cow milk allergy and / or food protein intolerance; and / or
(c) infections,
characterized in that non-digestible carbohydrates are selected from a source free of milk protein, bifidobacteria are free of milk protein, and the entire composition is substantially free of intact protein.

Images